MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells

Xiang,Fenfen; Wu,Rong; Ni,Zhenhua; Pan,Chunying; Zhan,Yueping; Xu,Jian; Meng,Xianpeng; Kang,Xiangdong

doi:10.3892/or.2014.3433

MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells

Authors:
- Fenfen Xiang
- Rong Wu
- Zhenhua Ni
- Chunying Pan
- Yueping Zhan
- Jian Xu
- Xianpeng Meng
- Xiangdong Kang
View Affiliations

Affiliations: Department of Laboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China, Central Laboratory, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China, Department of Ultrasound, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P.R. China
Published online on: August 21, 2014 https://doi.org/10.3892/or.2014.3433
Pages: 1837-1844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to investigate the relationship between myeloid differentiation primary response gene 88 (MyD88) expression and the resistance to paclitaxel of A549 lung cancer cells. In order to achieve MyD88 gene overexpression or knockdown in the A549 cell line, the cells were infected with lentivirus carrying MyD88 gene or shRNA to MyD88. MyD88 mRNA and protein expression was measured by RT-qPCR, immunohistochemistry and western blotting after infection for confirmation. Cell proliferation was detected by the WST-1 assay. Flow cytometry was used to measure the cell cycle and apoptosis. The transwell migration assay was used to observe the change of migration of transfected cells. The results showed that the overexpression of MyD88 increased the resistance of lung cancer A549 cells to paclitaxel, while the suppression of MyD88 increased the sensitivity of A549 lung cancer cells to paclitaxel. Following the paclitaxel treatment, a decreased apoptosis and G2 phase ratio, an increased cell migration ratio, and an increased production of IL-8 were found in MyD88‑overexpressed A549 cells. The western blot analysis revealed that Myd88 overexpression resulted in an increased level of Bcl-2 but a decreased level of Bax in A549 cells. These findings suggested that the expression level of MyD88 is closely associated with paclitaxel resistance in A549 lung cancer cells. Thus, the downregulation of MyD88 in A549 cells increased its sensitivity to paclitaxel treatment, whereas the upregulation of MyD88 substantiates its paclitaxel resistance.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Chen YT, Feng B and Chen LB: Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev. 13:3577–3581. 2012. View Article : Google Scholar : PubMed/NCBI
3	Volm M, Koomägi R, Mattern J, et al: Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer. 87:251–257. 2002. View Article : Google Scholar : PubMed/NCBI
4	Sun QL, Sha HF, Yang XH, et al: Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol. 137:521–532. 2011. View Article : Google Scholar : PubMed/NCBI
5	Kfoury A, Virard F, Renno T and Coste I: Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention. Curr Opin Oncol. 26:86–91. 2014. View Article : Google Scholar : PubMed/NCBI
6	Wang EL, Qian ZR, Nakasono M, et al: High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 102:908–915. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kelly MG, Alvero AB, Chen R, et al: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
8	Szajnik M, Szczepanski MJ, Czystowska M, et al: TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 28:4353–4363. 2009. View Article : Google Scholar : PubMed/NCBI
9	Silasi DA, Alvero AB, Illuzzi J, et al: MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med. 79:153–163. 2006.PubMed/NCBI
10	Duan Z, Feller AJ, Penson RT, et al: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 5:3445–3453. 1999.
11	Xiang WQ, Feng WF, Ke W, et al: Hepatitis B virus X protein stimulates IL-6 expression in hepatocytes via a MyD88-dependent pathway. J Hepatol. 54:26–33. 2011. View Article : Google Scholar : PubMed/NCBI
12	Szczepanski MJ, Czystowska M, Szajnik M, et al: Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 69:3105–3113. 2009. View Article : Google Scholar : PubMed/NCBI
13	Liang B, Chen R, Wang T, et al: Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res. 19:2905–2916. 2013. View Article : Google Scholar
14	Crown J and O’Leary M: The taxanes: an update. Lancet. 355:1176–1178. 2000. View Article : Google Scholar : PubMed/NCBI
15	Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
16	Horwitz SB, Lothstein L, Manfredi JJ, et al: Taxol: mechanisms of action and resistance. Ann NY Acad Sci. 466:733–744. 1986. View Article : Google Scholar : PubMed/NCBI
17	Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G₂/M. Mol Cell Biol. 19:8469–8478. 1999.PubMed/NCBI
18	Gonçalves A, Braguer D, Carles G, et al: Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol. 60:1579–1584. 2000.PubMed/NCBI
19	Castoldi A, Braga TT, Correa-Costa M, et al: TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis. PLoS One. 7:e375842012. View Article : Google Scholar : PubMed/NCBI
20	Haley K, Igyártó BZ, Ortner D, et al: Langerhans cells require MyD88-dependent signals for Candida albicans response but not for contact hypersensitivity or migration. J Immunol. 188:4334–4339. 2012. View Article : Google Scholar : PubMed/NCBI
21	Penson RT, Kronish K, Duan Z, et al: Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 10:33–41. 2000. View Article : Google Scholar : PubMed/NCBI
22	Arenberg DA, Kunkel SL, Polverini PJ, et al: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 97:2792–2802. 1996. View Article : Google Scholar : PubMed/NCBI